Abstracts tagged "takayasu arteritis and vasculitis"

Abstract Number: 1778 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease
Su Jin Choi¹, Doo-Ho Lim², Ji Seon Oh¹, Seokchan Hong¹, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: Systemic vasculitis is one of the major manifestations of Behcet’s disease (BD). Takayasu’s arteritis (TA) is a chronic vasculitis that primarily affects the aorta…
Abstract Number: 1882 • 2018 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Haruhito A. Uchida¹, Yoshikazu Nakaoka², Hajime Yoshifuji³, Takahiko Sugihara⁴, Yoshiko Watanabe⁵, Masayoshi Harigai⁶, Yoshihiro Arimura⁷ and Mitsuaki Isobe⁸, ¹Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ³Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁵First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁶Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ⁷Kyorin University School of Medicine, First Department of Internal Medicine, Tokyo, Japan, ⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Takayasu arteritis (TAK) typically affects young women under 40 years old, whereas patients with onset age over 40 years are occasionally observed. It still…
Abstract Number: 2781 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
Sema Kaymaz Tahra¹, Fatma Alibaz-Oner¹ and Haner Direskeneli², ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral center. Methods: In this…
Abstract Number: 785 • 2017 ACR/ARHP Annual Meeting
Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Lindsy J. Forbess⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Robert F. Spiera¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁴, Carol A. Langford¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁶Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose : Longitudinal data on the type, progression, and predictors of arterial lesions in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to…
Abstract Number: 796 • 2017 ACR/ARHP Annual Meeting
Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Laure Delaval^1,2, Aurélie Daumas³, Maxime Samson⁴, Mikael Ebbo⁵, Hubert de Boysson⁶, Eric Liozon⁷, Henry Dupuy⁸, Alexis Regent⁹, Mathieu Puyade¹⁰, Daniel Blockmans¹¹, Estibaliz Lazaro¹², Ygal Benhamou¹³, Karim Sacre¹⁴, Alice Bérezné¹⁵, Loïc Guillevin^2,9,16 and Benjamin Terrier^17,18,19, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Marseille, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵internal medicine, Aix-Marseille Université, La Timone University Hospital, AP-HM, Paris, France, ⁶Department of Internal Medicine, Caen University Hospital, Caen, France, ⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁰Department of Internal Medicine, University Hospital of Poitiers, Poitiers, France, ¹¹General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ¹²Department of Internal Medecine and Clinical Immunology, Bordeaux University Hospital, Pessac, France, ¹³Department of internal medicine, University Hospital of Rouen, Rouen, France, ¹⁴Department of Internal Medicine, Bichat Hospital, Paris, France, ¹⁵Department of internal medicine, CHR Annecy-Genevois, Metz-Tessy, France, ¹⁶French Vasculitis Study Group (FVSG), Paris, France, ¹⁷Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁸Internal Medicine, Cochin University Hospital, Paris, France, ¹⁹French Vasculitis Study Group (FVSG), paris, France
Background/Purpose: Primary large-vessel vasculitis (LVV) include giant cell arteritis (GCA) and Takayasu arteritis (TA). Age at onset is commonly used to distinguish GCA and TA.…
Abstract Number: 820 • 2017 ACR/ARHP Annual Meeting
Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis
Peter C. Grayson¹, Sara Alehashemi², Armin Bagheri³, Ali Cahid Civelek⁴, Thomas Cupps⁵, Mariana J. Kaplan⁶, Ashkan Malayeri⁴, Peter A. Merkel⁷, Elaine Novakovich⁸, David A. Bluemke⁴ and Mark Ahlman⁴, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rheumatology, Georgetown University, Bethesda, MD, ⁶NIAMS/NIH, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, MN, ⁸Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: While several studies have examined the potential of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) to help establish a diagnosis of large vessel vasculitis (LVV),…
Abstract Number: 821 • 2017 ACR/ARHP Annual Meeting
Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis
Peter C. Grayson¹, Mark Ahlman², Kathleen Marinelli³, Renee Borchin⁴, Simon Carette⁵, Nader A. Khalidi⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Christian Pagnoux⁵, Kenneth J. Warrington¹⁰, Steven R. Ytterberg¹⁰ and Peter A. Merkel¹¹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³NIAMS, National Institutes of Health, Bethesda, MD, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology, Mayo Clinic, Rochester, MN, ¹¹Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To study the relationship between clinically-determined disease activity and vascular inflammation assessed by positron emission tomography (PET) in patients with TakayasuÕs arteritis (TAK). Methods:…
Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Anne-Claire Desbois¹, Valentin Quiniou², Patrick Bruneval³, Nicolas Derian², Anna Maciejewski-Duval², Marlène Garrido⁴, Cloé Comarmond⁵, Jacques Pouchot⁶, Michelle Rosenzwajg², David Klatzmann², Patrice Cacoub⁷ and David Saadoun⁸, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²GHPS, Paris, France, ³HEGP, Paris, France, ⁴I3 laboratory, Pitié-Salpétrière, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶Internal Medicine Department, European Hospital Georges Pompidou, Paris, France, ⁷Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁸Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…
Abstract Number: 1746 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Activation in Takayasu Arteriti
Cloé Comarmond¹, Aurélie Leroyer², Zeidan Mohamad³, Jean-Pierre Fourez⁴, Fabien Koskas⁵, Philippe Cluzel⁶, Anna Maciejewski-Duval⁷, Marlène Garrido⁸, Patrice Cacoub⁹ and David Saadoun¹⁰, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hopital de Marseille, Marseille, France, ³Hopital Necker, Paris, France, ⁴Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁵Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ⁷GHPS, Paris, France, ⁸I3 laboratory, Pitié-Salpétrière, Paris, France, ⁹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹⁰Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: mTORC1 drives the proinflammatory expansion of T helper (TH) type 1, TH17 cells and controls fibroblast proliferation, typical features of Takayasu arteritis (TA) pathogenesis.…
Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Jérôme Hadjadj¹, Guillaume Canaud², Tristan Mirault³, Maxime Samson⁴, Patrick Bruneval⁵, Alexis Regent⁶, Claire Goulvestre⁷, Veronique Witko-Sarsat⁸, Nathalie Costedoat-Chalumeau⁹, Loïc Guillevin for the French Vasculitis Study Group¹⁰, Luc Mouthon¹¹ and Benjamin Terrier¹², ¹Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, Paris, France, Paris, France, ²Department of Nephrology and Transplantation, Necker-Enfants Malade, Université Paris Descartes, Sorbonne Paris Cité, INSERM U1151, Necker-Enfants Malades Hospital, Paris, France AP-HP, Paris, France, PARIS, France, ³Department of Vascular Medicine, Georges Pompidou European Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, Paris, France, ⁴Dijon University Hospital, Dijon, France, ⁵HEGP, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁷Department of Immunology, Hospital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁸Team Neutrophils and Vasculitis, INSERM U1016, Cochin Institute, LABEX Inflamex, Université Sorbonne Paris Cité, 75013, Paris, France, Paris, France, ⁹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ¹²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…
Abstract Number: 71 • 2017 ACR/ARHP Annual Meeting
The Critical Role of Interleukin-33 in Promoting Angiogenesis and Regulates Inflammation through Mast Cells in Takayasu Arteritis
Anne-Claire Desbois¹, Patrice Cacoub², Aurélie LEROYER³, Edwige Tellier⁴, Marlène Garrido⁵, Anna Maciejewski-Duval⁶, Cloé Comarmond⁷, Stéphane Barete⁶, Michel Arock⁶, Patrick Bruneval⁸, Jean-Marie Launay⁹, Pierre Fouret¹⁰, Ulrich Blank¹¹, Michelle Rosenzwajg⁶, David Klatzman¹², Mohamed Jarraya¹³, Philippe Cluzel¹⁴, Fabien Koskas¹⁵, Gilles Kaplanski¹⁶ and David Saadoun¹⁷, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³Faculté de Pharmacie, Marseille, France, ⁴Université Marseille, Marseille, France, ⁵I3 laboratory, Pitié-Salpétrière, Paris, France, ⁶GHPS, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁸HEGP, Paris, France, ⁹Hôpital lariboisière, Paris, France, ¹⁰Hôpital La Pitié Salpétrière, Paris, France, ¹¹Hôpital Bichat, Paris, France, ¹²UPMC Université Paris 06, UMR 7211, Paris, France, ¹³Hôpital Saint Louis, Paris, France, ¹⁴Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ¹⁵Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ¹⁶Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹⁷Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: Large vessel vasculitis (LVV) include Takayasu arteritis (TA) and giant cell arteritis (GCA). Arterial lesions in LVV result from chronic inflammation and neoangiogenesis. IL-33,…
Abstract Number: 784 • 2017 ACR/ARHP Annual Meeting
Damage and Predictors of Damage in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel^1,14, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Information regarding the degree and the predictors of damage in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to characterize damage and…
Abstract Number: 859 • 2016 ACR/ARHP Annual Meeting
Long-Term Outcomes of Renal Artery Involvement in Takayasu Arteritis
Seokchan Hong¹, Oh Chan Kwon², Byeongzu Ghang³, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Long-term Outcomes of Renal Artery Involvement in Takayasu Arteritis Background/Purpose: Takayasu arteritis (TA) involving the renal artery can result in hypertension, renal dysfunction, and premature…
Abstract Number: 860 • 2016 ACR/ARHP Annual Meeting
Assessment of the Frequency of Cardiovascular Risk Factors in Patients with Takayasu’s Arteritis
Fatma Alibaz-Oner¹, Matthew J. Koster², Ali Ugur Unal³, Hale Gulcin Yildirim⁴, Ceylan Cikikci⁴, Cynthia S. Crowson⁵, Ashima Makol⁶, Steven R. Ytterberg⁶, Eric L. Matteson⁶, Haner Direskeneli⁷ and Kenneth J. Warrington⁶, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Accelerated atherosclerosis associated with chronic inflammation is one of the major complications of systemic inflammatory diseases. Takayasu arteritis (TAK) is a rare, systemic large-vessel…
Abstract Number: 881 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Involvement in Takayasu Arteritis
David Brennan¹, Kenneth J. Warrington², Jean Schmidt³, Cynthia S. Crowson⁴ and Matthew J. Koster⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN
Background/Purpose: Takayasu arteritis (TAK) is an inflammatory large-vessel vasculitis of unknown etiology affecting the proximal aorta and its primary branches. Heart disease is a major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].